JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") announced today that it will present at the 21st Annual WORLDSymposiumtm 2025, held February 3-7, 2025, in San Diego, Calif. The poster presentations ...

Catch up with the latest from the Mississippi legislative session with our weekly recap from the politics team.

Last year, they successfully lobbied against the confirmation of Gary Skiba, a hunter, angler, bighorn sheep biologist, and 23-year veteran of Colorado Parks and Wildlife, because he supported wolf ...

The human remains match 18-year-old Joey Fujioka, who went missing on Ke Iki Beach. Patrick Mahomes is facing a personal ...

What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

Scientists have discovered a surprising mechanism by which the inherited genetic mutation known to cause Huntington's disease leads to the death of brain cells. The findings change the understanding ...

Take all NFL insider reports with a grain of salt. There are two types of sources for those who trade in league secrets; ownership and agents. Both sides always have an agenda. When ownership is ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

The partnership will focus on advancing RGX-121 as a treatment for mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for treating mucopolysaccharidosis I (MPS I), also ...

One of the treatments, for a progressive disorder known as Hunter syndrome, could secure approval in the U.S. as soon as late this year. Should that happen, Regenxbio will retain rights to any ...

The ultimate goals of treatment include decreasing androgen levels to improve hirsutism, protecting the endometrium, optimizing reproductive function in those desiring fertility, and reducing the ...

Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).